Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2013-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2125.2012.04471.xPMID 23013236PMCID PMC3635595
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biochemical Markers of Bone Turnover in the Clinical Development of Drugs for Osteoporosis and Metastatic Bone Disease

  2012cited by this paper
• Quantitative determination of odanacatib in human plasma using liquid-liquid extraction followed by liquid chromatography-tandem mass spectrometry analysis.

  2012cited by this paper
• Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys

  2012cited by this paper
• Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey

  2012cited by this paper
• Efficacy and safety of the cathepsin K inhibitor, ONO-5334, and alendronate on post-menopausal osteopenia or osteoporosis: 2-year results from the ocean study

  2011cited by this paper
• Safety and efficacy of the cathepsin K inhibitor ONO‐5334 in postmenopausal osteoporosis: The OCEAN study

  2011cited by this paper
• Cathepsin K inhibitors prevent bone loss in estrogen‐deficient rabbits

  2011cited by this paper
• Pharmacokinetics and Metabolism in Rats, Dogs, and Monkeys of the Cathepsin K Inhibitor Odanacatib: Demethylation of a Methylsulfonyl Moiety as a Major Metabolic Pathway

  2011cited by this paper
• Successes Achieved and Challenges Ahead in Translating Biomarkers into Clinical Applications

  2010cited by this paper
• Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double‐Blind, Randomized, Placebo‐Controlled Phase I Studies

  2009cited by this paper
• Bone density, strength, and formation in adult cathepsin K (-/-) mice.

  2009cited by this paper
• Bone markers in osteoporosis

  2009cited by this paper
• Basic science and clinical utility of biochemical markers of bone turnover--a Congress report.

  2009cited by this paper
• Cathepsin K Inhibitors: A Novel Target for Osteoporosis Therapy

  2008cited by this paper
• Biomarkers for Osteoporosis Management

  2008cited by this paper
• The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

  2008cited by this paper
• High bone mineral density in pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K

  2007cited by this paper
• Guidelines for diagnosis and management of osteoporosis

  2005cited by this paper
• The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.

  2005cited by this paper
• The Bone Lining Cell: Its Role in Cleaning Howship's Lacunae and Initiating Bone Formation

  2002cited by this paper
• Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K.

  2000cited by this paper
• Proteinases in bone resorption: obvious and less obvious roles.

  2000cited by this paper
• A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover.

  1999cited by this paper
• Epidemiology of Osteoporosis

  1999cited by this paper
• The Collagenolytic Activity of Cathepsin K Is Unique among Mammalian Proteinases*

  1998cited by this paper
• Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice.

  1998cited by this paper
• Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease.

  1997cited by this paper
• THE EPIDEMIOLOGY OF OSTEOPOROSIS

  1996cited by this paper
• Perspectives: How many women have osteoporosis now?

  1995cited by this paper
• Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.

  1994cited by this paper

• Domain adversarial gated bilinear attention networks for cross domain drug target interaction prediction.

  2026cites this paper
• Efficacy and Safety of ARB-Based Combination Therapies for Treatment of Hypertension: A Systematic Review and Meta-analyses.

  2026cites this paper
• Cathepsin K Inhibitors as Potential Drugs for the Treatment of Osteoarthritis

  2025cites this paper
• Review of Cathepsin K Inhibitor Development and the Potential Role of Phytochemicals

  2024cites this paper
• Interaction mechanism of a cysteine protease inhibitor, odanacatib, with human serum albumin: In vitro and bioinformatics studies.

  2023cites this paper
• Bioactives and Biomaterial Construction for Modulating Osteoclast Activities

  2023cites this paper
• Cathepsin K: A Versatile Potential Biomarker and Therapeutic Target for Various Cancers

  2022cites this paper
• The role of endolysosomal trafficking in anticancer drug resistance.

  2021cites this paper
• The Pathophysiology of Osteoporosis after Spinal Cord Injury

  2021cites this paper
• Bone turnover markers as determinants of bone density and fracture in men with distal forearm fractures: the pathogenesis examined in the Mr F study

  2021cites this paper
• Osteoporosis therapies and their mechanisms of action (Review)

  2021cites this paper
• A Combined approach of QSAR study, molecular docking and pharmacokinetics prediction of promising Amide-Ac6-aminoacetonitriles Cathepsin K inhibitors

  2021cites this paper
• A phase 1 pooled PK/PD analysis of bone resorption biomarkers for odanacatib, a Cathepsin K inhibitor

  2020cites this paper
• Bone turnover markers

  2020cites this paper
• Population Pharmacokinetic Analysis of the Cathepsin K Inhibitor Odanacatib: Insights Into Intrinsic and Extrinsic Factor Effects on Exposure in Postmenopausal and Elderly Women

  2020cites this paper
• Bone Turnover Markers Do Not Predict Fracture Risk in Type 2 Diabetes

  2020cites this paper
• Pharmacometrics and systems pharmacology for metabolic bone diseases.

  2019influential citation
• Design, synthesis and biological evaluation of inhibitors of cathepsin K on dedifferentiated chondrocytes.

  2019cites this paper
• Effects of the Cathepsin K Inhibitor ONO-5334 and Concomitant Use of ONO-5334 with Methotrexate on Collagen-Induced Arthritis in Cynomolgus Monkeys

  2019cites this paper
• Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects

  2019cites this paper
• Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.

  2019cites this paper
• Cysteine proteases in protozoan parasites

  2018cites this paper
• Regulatory Perspectives in Pharmacometric Models of Osteoporosis

  2018cites this paper
• Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711

  2018cites this paper
• Theoretical studies on the interaction between the nitrile-based inhibitors and the catalytic triad of Cathepsin K

  2018cites this paper
• Odanacatib Pharmacokinetics Comparison Between Chinese and Non‐Chinese Postmenopausal Women

  2018cites this paper
• Future Therapies

  2018cites this paper
• Therapeutic Drugs in Bone Loss-Associated Disorders: Clinical Outcomes and Challenges.

  2017cites this paper
• Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability

  2017cites this paper
• Physicochemical properties of dietary phytochemicals can predict their passive absorption in the human small intestine

  2017cites this paper
• The human pharmacokinetics of odanacatib, a novel cathepsin K inhibitor, predicted by interspecies scaling: a retrospective analysis

  2017cites this paper
• Odanacatib Inhibits Resistin-induced Cardiomyocyte Hypertrophy Through the Inactivation of ERK Signaling Pathway

  2017cites this paper
• Odanacatib Inhibits Resistin-induced Hypertrophic H9c2 Cardiomyoblast Cells Through LKB1/AMPK Pathway

  2017cites this paper
• Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis

  2017cites this paper
• Synthesis and biological evaluation of a water-soluble phosphate prodrug salt and structural analogues of KGP94, a lead inhibitor of cathepsin L.

  2017cites this paper
• Applicability of in vitro-in vivo translation of cathepsin K inhibition from animal species to human with the use of free-drug hypothesis

  2017cites this paper
• Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned

  2017cites this paper
• New therapies in osteoporosis

  2016cites this paper
• Nuevas terapias en osteoporosis

  2016cites this paper
• Discovery of a New Class of Cathepsin K Inhibitors in Rhizoma Drynariae as Potential Candidates for the Treatment of Osteoporosis

  2016cites this paper
• Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.

  2016cites this paper
• Screening of Protease Inhibitory Activity in Aqueous Extracts of Marine Invertebrates from Cuban Coast

  2016cites this paper
• Key words postmenopausal women , osteoporosis , bone density , pharmacological therapy , fracture

  2016cites this paper
• Cathepsin K osteoporosis trials, pycnodysostosis and mouse deficiency models: Commonalities and differences

  2016cites this paper
• Journal of the Malta College of Pharmacy Practice

  2016cites this paper
• The Absolute Bioavailability and Effect of Food on the Pharmacokinetics of Odanacatib: A Stable-Label i.v./Oral Study in Healthy Postmenopausal Women

  2016cites this paper
• Nanoparticles-Based Treatment for Bone Metastasis.

  2016cites this paper
• The role of Cathepsin K in haematopoiesis

  2016cites this paper
• Identification of novel cathepsin K inhibitors using ligand-based virtual screening and structure-based docking

  2016cites this paper
• Molecular Design, Synthesis and Trypanocidal Activity of Dipeptidyl Nitriles as Cruzain Inhibitors

  2015cites this paper
• Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis

  2015cites this paper
• Multicentric Reticulohistiocytosis: a Critical Review

  2015cites this paper
• Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial

  2015cites this paper
• Development and validation of an RP-HPLC method for the quantitation of odanacatib in rat and human plasma and its application to a pharmacokinetic study.

  2015cites this paper
• Cathepsin L Mediates the Degradation of Novel APP C-Terminal Fragments.

  2015cites this paper
• Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inhibitors.

  2015cites this paper
• New treatments of osteoporosis

  2015cites this paper
• Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L.

  2015cites this paper
• Odanacatib: An Emerging Novel Treatment Alternative for Postmenopausal Osteoporosis

  2015cites this paper
• Odanacatib for the treatment of osteoporosis

  2015influential citation
• Azanitrile Cathepsin K Inhibitors: Effects on Cell Toxicity, Osteoblast-Induced Mineralization and Osteoclast-Mediated Bone Resorption

  2015cites this paper
• Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women.

  2014cites this paper
• Combined batch and continuous flow procedure to the chemo-enzymatic synthesis of biaryl moiety of Odanacatib

  2014cites this paper
• Mechanistic interpretation of artificial neural network‐based QSAR model for prediction of cathepsin K inhibition potency

  2014cites this paper
• Small molecules regulated bone resorption and enzyme activity in osseous cells

  2014cites this paper
• DMD056580 818..827

  2014cites this paper
• Cysteine cathepsins and extracellular matrix degradation.

  2014cites this paper
• Modulation of osteoclast differentiation and bone resorption by Rho GTPases

  2014cites this paper
• Recent Advances in the Formation and Activation of Osteoclasts

  2014cites this paper
• Effect of odanacatib on BMD and fractures: estimates from Bayesian univariate and bivariate meta-analyses.

  2014cites this paper
• Disposition and Metabolism of the Cathepsin K Inhibitor Odanacatib in Humans

  2014cites this paper
• Die Kieferosteonekrose als Komplikation der antiresorptiven Therapie

  2014cites this paper
• Predicting patient-to-patient variability in proteolytic activity and breast cancer progression

  2014cites this paper
• Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

  2014cites this paper
• Osteoporosis in older persons: current pharmacotherapy and future directions

  2013cites this paper
• Cathepsin K: a unique collagenolytic cysteine peptidase

  2013cites this paper
• Reversible Cysteine Protease Inhibitors Show Promise for a Chagas Disease Cure

  2013cites this paper
• DEPARTAMENTO DE ANATOMÍA Y RADIOLOGÍA

  2013cites this paper
• Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts

  2013cites this paper
• Odanacatib does not influence the single dose pharmacokinetics and pharmacodynamics of warfarin.

  2013cites this paper
• Endocrinology and diabetes

  2002cites this paper